Invention Grant
- Patent Title: Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
-
Application No.: US17502962Application Date: 2021-10-15
-
Publication No.: US12083112B2Publication Date: 2024-09-10
- Inventor: Andrew Evan Denker , Yu Kato , Kimiyo Tabata , Yusaku Hori
- Applicant: MERCK SHARP & DOHME LLC , EISAI R&D MANAGEMENT CO., LTD.
- Applicant Address: US NJ Rahway
- Assignee: EISAI R&D MANAGEMENT CO., LTD.,Merck Sharp & Dohme LLC
- Current Assignee: EISAI R&D MANAGEMENT CO., LTD.,Merck Sharp & Dohme LLC
- Current Assignee Address: JP Tokyo; US NJ Rahway
- Agency: MARSHALL, GERSTEIN & BORUN LLP
- Priority: JP 15042683 2015.03.04 JP 15114890 2015.06.05
- Main IPC: A61K39/00
- IPC: A61K39/00 ; A61K31/47 ; A61K39/395 ; A61K45/06 ; C07K16/28
Abstract:
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a multi-RTK inhibitor, and the use of the combination therapies for the treatment of cancer. The multi-RTK inhibitor may be represented by Formula (I):
wherein R1 is C1-6 alkyl or C3-8 cycloalkyl, R2 is a hydrogen atom or C1-6 alkoxy, and R3 is a hydrogen atom or a halogen atom. A tumor therapeutic agent is disclosed that combines a compound or pharmaceutically acceptable salt thereof represented by Formula I and an anti-PD-1 antibody.
wherein R1 is C1-6 alkyl or C3-8 cycloalkyl, R2 is a hydrogen atom or C1-6 alkoxy, and R3 is a hydrogen atom or a halogen atom. A tumor therapeutic agent is disclosed that combines a compound or pharmaceutically acceptable salt thereof represented by Formula I and an anti-PD-1 antibody.
Public/Granted literature
- US20220023285A1 COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR/FGFR/RET TYROSINE KINASE INHIBITOR FOR TREATING CANCER Public/Granted day:2022-01-27
Information query
